Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Tammie C. Yeh, Vivienne Marsh, Bryan A. Bernat, +13

Clinical Cancer Research

Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation

Kurtis D. Davies, P. LouAnn Cable, Jennifer Garrus, +5

Cancer Biology & Therapy

Cell DeathCell CycleSirna ScreenTumor BiologyChk1 Inhibition +19

Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor

Patrice A. Lee, Eli Wallace, Allison Marlow, +10

Cancer Research

ImmunologyPharmacotherapySelective Mek 1/2Cancer BiologyTumor Biology +16

Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

Anna E. Maciag, James P. Stice, Bin Wang, +30

Cancer Discovery

Molecular BiologyDirect Target CoverageAdaptive ResistanceTumor BiologyReceptor Tyrosine Kinase +17

Diaminoindanes as Microsomal Triglyceride Transfer Protein Inhibitors

Gary M. Ksander, Reynalda deJesus, Andrew Yuan, +22

Journal of Medicinal Chemistry

Metabolic SyndromeLipid SynthesisBiochemistryMtp InhibitorsMedicine +10

Single-Agent Inhibition of Chk1 Is Antiproliferative in Human Cancer Cell Lines In Vitro and Inhibits Tumor Xenograft Growth In Vivo

Kurtis D. Davies, Michael Humphries, Francis X. Sullivan, +9

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics

Tumor BiologyOncologySingle-agent InhibitionChk1 Is AntiproliferativeChemoprevention Strategy +13

Abstract #1795: In Vitro and in vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB2.

Tracy Pheneger, Karyn Bouhana, Deborah Anderson, +17

Cancer Research

Small Molecule InhibitorPharmacotherapyTumor BiologyTranslational PharmacologyMolecular Pharmacology +18

Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR

Alok K. Sharma, Jun Pei, Yue Yang, +13

Journal of Biological Chemistry

Abstract A143: ARRY-380, a selective HER2 inhibitor: From drug design to clinical evaluation.

Stacy L. Moulder, Tara Baetz, Virginia F. Borges, +9

Molecular Cancer Therapeutics

Preclinical development of ARRY-142886, a potent and selective MEK inhibitor

Eli Wallace, Tammie C. Yeh, Joe Lyssikatos, +22

Cancer Research

PharmacotherapyCancer BiologyTumor BiologyTime Tumor GrowthMolecular Pharmacology +19